SPOTLIGHT -
Clinical practice experience is confirming the results from premarketing clinical trials that showed a new over-the-counter artificial tear product (Systane, Alcon) is a novel approach for modulating the signs and symptoms of dry eye.
Making the grade: FDA approves first biosimilar product for retinal diseases
Advancement in TED treatment is a bright spot
Comparable conscious sedation methods address individual patient needs
Investigators uncover health care disparities among US patients
Investigators zoom in on future of dry eye treatment
Analyzing opioid prescription patterns of US retina specialists